Russell Frank Company’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Russell Frank Company’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-20,261	Closed	-$126K	–	3078
2015 Q4	$126K	Sell	20,261 -184,201	-90%	-$1.21M	﹤0.01%	2773
2015 Q3	$1.17M	Sell	204,462 -62,783	-23%	-$482K	﹤0.01%	2128
2015 Q2	$1.99M	Buy	267,245 +138,672	+108%	+$839K	﹤0.01%	1970
2015 Q1	$769K	Sell	128,573 -159,885	-55%	-$1.01M	﹤0.01%	2269
2014 Q4	$2.09M	Buy	+288,458	New	+$1.73M	﹤0.01%	1771
2013 Q4	–	Sell	-7,985	Closed	-$40K	–	3181
2013 Q3	$40K	Buy	7,985 +2,947	+58%	+$16K	﹤0.01%	3149
2013 Q2	$22K	Buy	+5,038	New	+$22.6K	﹤0.01%	2989

Other funds holding PGNX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Russell Frank Company's PGNX Position: Q1 2016 in Review

Russell Frank Company sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2016, closing a stake of 20,261 shares — an estimated $126K sold.

Russell Frank Company first reported a position in PGNX in Q2 2013 and held it in 7 quarters. The position peaked at $2.09M in Q4 2014. 120 funds tracked by Wall St. Rank hold PGNX as of Q1 2016.

Russell Frank Company reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
Russell Frank Company sold 20,261 Progenics Pharmaceuticals Inc shares in Q1 2016, an estimated $126K.
Russell Frank Company first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 7 quarters.
Russell Frank Company's Progenics Pharmaceuticals Inc position peaked at $2.09M in Q4 2014.
120 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.